Clinical Trial Update: Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease [Phase 3]

View source ↗

Summary

Phase 3 study evaluating PRX-102 for gastrointestinal symptoms in Fabry disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• PRX-102

Snippet

Sponsor: Protalix | Conditions: Fabry Disease | Phase 3 | Status: WITHDRAWN